Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
1939-1989, fifty years progress in allergy : a tribute to Paul Kallós
| 1939-1989, fifty years progress in allergy : a tribute to Paul Kallós |
| Pubbl/distr/stampa | [Place of publication not identified], : Karger, 1990 |
| Descrizione fisica | 1 online resource (XII + 284 pages) : : 47 figures, 16 tables |
| Collana | Chemical immunology 1939-1989, fifty years progress in allergy |
| Soggetto topico |
Allergy
Immunologic diseases Immune System Diseases Medicine Diseases Health Occupations Disciplines and Occupations Allergy and Immunology Hypersensitivity Health & Biological Sciences Clinical Immunology |
| ISBN | 3-318-01627-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910155293703321 |
| [Place of publication not identified], : Karger, 1990 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
[Medical text, in part discussing gout, written in English and Latin] [[electronic resource]]
| [Medical text, in part discussing gout, written in English and Latin] [[electronic resource]] |
| Pubbl/distr/stampa | [S.l., : s.n., before 1700?] |
| Descrizione fisica | [2] p |
| Soggetto topico |
Diseases
Gout |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996393727703316 |
| [S.l., : s.n., before 1700?] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Accompany Me : A Life in Vulnerability and Faith
| Accompany Me : A Life in Vulnerability and Faith |
| Autore | Gallagher Nora |
| Pubbl/distr/stampa | , : Knopf Doubleday Publishing Group, , 2017 |
| Descrizione fisica | 1 online resource (37 pages) |
| Disciplina | 616.00189999999998 |
| Collana | A Vintage Short |
| Soggetto topico |
Critically ill
Diseases Adjustment (Psychology) |
| ISBN | 0-525-43516-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910163079303321 |
Gallagher Nora
|
||
| , : Knopf Doubleday Publishing Group, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Acquired immunodeficiency syndrome
| Acquired immunodeficiency syndrome |
| Pubbl/distr/stampa | [Place of publication not identified], : Karger, 1986 |
| Descrizione fisica | 1 online resource (X + 398 pages) : : 103 figures, 29 tables |
| Soggetto topico |
Slow Virus Diseases
HIV Infections Immunologic Deficiency Syndromes Sexually Transmitted Diseases, Viral Lentivirus Infections Virus Diseases Diseases Retroviridae Infections Sexually Transmitted Diseases Immune System Diseases RNA Virus Infections Acquired Immunodeficiency Syndrome |
| ISBN | 3-318-01862-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910155293603321 |
| [Place of publication not identified], : Karger, 1986 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Acute stroke : evaluation and treatment
| Acute stroke : evaluation and treatment |
| Pubbl/distr/stampa | [Place of publication not identified], : AHRQ, 2005 |
| Descrizione fisica | 1 online resource |
| Collana |
Evidence Reports/Technology Assessments
AHRQ publication |
| Soggetto topico |
Cerebrovascular Disorders
Drug Therapy Brain Diseases Vascular Diseases Therapeutics Diagnostic Techniques and Procedures Central Nervous System Diseases Cardiovascular Diseases Nervous System Diseases Diseases Stroke Thrombolytic Therapy Medicine Health & Biological Sciences Neurology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910698112503321 |
| [Place of publication not identified], : AHRQ, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910133588303321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910830164603321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910841604803321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Adolescents, alcohol, and substance abuse : reaching teens through brief interventions
| Adolescents, alcohol, and substance abuse : reaching teens through brief interventions |
| Pubbl/distr/stampa | [Place of publication not identified], : Guilford Press, 2001 |
| Descrizione fisica | 1 online resource (683 pages) |
| Disciplina | 616.86/00835 |
| Soggetto topico |
Teenagers - Substance use
Teenagers - Alcohol use Substance abuse - Prevention Alcoholism - Prevention Brief psychotherapy for teenagers - Counseling of Teenagers Age Groups Mental Disorders Diseases Psychotherapy Behavioral Disciplines and Activities Persons Psychiatry and Psychology Named Groups Psychotherapy, Brief Substance-Related Disorders Adolescent Medicine Health & Biological Sciences Pediatrics |
| ISBN | 1-4625-0597-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover -- Title Page -- Copyright Page -- Dedication -- About the Editors -- Contributors -- Foreword -- Preface -- Contents -- Introduction -- PART I. BACKGROUND AND CONTEXT: THEORY, DEVELOPMENTAL, AND MEASUREMENT CONSIDERATIONS -- 1. Development Matters: Taking the Long View on Substance Abuse Etiology and Intervention during Adolescence -- 2. The Harm Reduction Approach to the Secondary Prevention of Alcohol Problems in Adolescents and Young Adults: Considerations across a Developmental Spectrum -- 3. Assessing Adolescent Substance Use Problems and Other Areas of Functioning: State of the Art -- 4. Personality and Learning Factors Combine to Create Risk for Adolescent Problem Drinking: A Model and Suggestions for Intervention -- PART II. EMPIRICAL ILLUSTRATIONS LINKED TO PART 1/ CLINICAL APPLICATIONS OF BRIEF INTERVENTIONS -- 5. Motivational Enhancement for Alcohol-Involved Adolescents -- 6. Alcohol Skills Training for College Students -- 7. Integrative Behavioral and Family Therapy for Adolescent Substance Abuse -- 8. Motivational Interviewing and the Prevention of HIV among Adolescents -- 9. Toward Brief Interventions for Adolescents with Substance Abuse and Comorbid Psychiatric Problems -- 10. New Frontiers: Using the Internet to Engage Teens in Substance Abuse Prevention and Treatment -- PART III. FUTURE DIRECTIONS -- 11. Transdisciplinary Research to Improve Brief Interventions for Addictive Behaviors -- Index -- About Guilford Publications -- Discover More Guilford Titles. |
| Altri titoli varianti | Adolescents, Alcohol, and Substance Abuse |
| Record Nr. | UNINA-9910162831003321 |
| [Place of publication not identified], : Guilford Press, 2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced Therapy for Hepatitis C [[electronic resource]]
| Advanced Therapy for Hepatitis C [[electronic resource]] |
| Autore | McCaughan Geoffrey W |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (233 p.) |
| Disciplina |
616.3/62306
616.362306 |
| Altri autori (Persone) |
McHutchisonJohn
PawlotskyJean-Michel |
| Soggetto topico |
Antiviral agents
Antiviral Agents - therapeutic use Antiviral Agents -- therapeutic use Hepatitis C - therapy Hepatitis C -- therapy Hepatitis C - Treatment Hepatitis C -- Treatment Hepatitis, Viral, Human Flaviviridae Infections Anti-Infective Agents RNA Virus Infections Therapeutic Uses Virus Diseases Hepatitis Diseases Liver Diseases Pharmacologic Actions Chemical Actions and Uses Digestive System Diseases Antiviral Agents Hepatitis C Medicine Health & Biological Sciences Gastroenterology |
| ISBN |
1-283-28323-9
9786613283238 1-4443-4634-2 1-4443-4631-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Advanced Therapy for Hepatitis C; Contents; Contributors; Preface; Section I Foundations for Understanding Antiviral Therapies in HCV; 1 HCV Replication; 2 Hepatitis C Virus Genotypes; 3 Immune Responses to HCV: Implications for Therapy; 4 Mechanisms of Action of Antiviral Drugs: The Interferons; 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs; 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors; 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors; 8 Measuring Antiviral Responses
Section II Efficacy and Clinical Use of Antiviral Therapies9 Genotype 1: Standard Treatment; 10 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients; 11 Genotype 1 Relapsers and Non-responders; 12 Standard Therapy for Genotypes 2/3; 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3; 14 Genotypes 2 and 3 Relapse and Non-response; 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges; 16 Antivirals in Acute Hepatitis C; 17 Antivirals in Cirrhosis and Portal Hypertension 18 Treatment of Recurrent Hepatitis C Following Liver Transplantation19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations; 20 Cytopenias: How they Limit Therapy and Potential Correction; 21 The Problem of Insulin Resistance and its Effect on Therapy; 22 HIV and Hepatitis C Co-infection; 23 HCV and Racial Differences; 24 HCV and the Pediatric Population; 25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV; Index |
| Record Nr. | UNINA-9910139591503321 |
|
McCaughan Geoffrey W
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Diseases
(688)
- Health & Biological Sciences (330)
- Medicine (249)
- Health Care (146)
- Public Health (122)